
AdaptVac receives InnoBooster grant to support pre-clinical development of a HER2 viral capsid-like particle vaccine (AV001)

Hørsholm, Denmark, October 17, 2019 – AdaptVac announces that it has been awarded an InnoBooster grant by the Danish Innovation Foundation worth 0.8M DKK. The grant provides further support for the viral-capsid based vaccine platform technology by potentially demonstrating a safe and effective treatment for pet dogs diagnosed with DER2+ cancer, the canine protein homologous to human epidermal growth factor receptor 2 (HER2). This project forms part of our pre-clinical development in support of a human clinical development program.

“The expanded support from Danish Innovation Foundation will allow us to accelerate our development and gain valuable data in support of the safety and efficacy in pet dogs with DER2+ cancer.” says Dr. Wian de Jongh, AdaptVac’s CEO.

The aim of the project is to develop a veterinary product and at the same time generate supportive data for human clinical development. Therefore, the program will derisk further development making the HER2 cancer vaccine attractive to partnering or licencing within both the veterinary and human vaccine market.

Market potential in veterinary market

More than 6 million dogs develops cancer each year in the US alone. The potential market for treating canine cancer is growing due to increasing number of canine healths insurances. HER2 is a relevant target in a number of cancer indications, e.g. canine osteosarcoma, and canine mammary cancer. AdaptVac plans to establish a collaboration with a large veterinary company upon successful proof-of-concept in dogs. The potential value of such a deal can be benchmarked by the 2014 Advaxis/Aratana deal in 2014, which had an accumulated value of 37 million USD for a vaccine portfolio including DER2+ canine cancer.

(for more information, See <https://aratana.investorroom.com/2014-03-19-Aratana-and-Advaxis-Enter-Exclusive-Global-Licensing-Agreement>)

Strong market potential in breast cancer

Breast cancer is a widespread oncology indication affecting more than 1.3 million worldwide annually, resulting in more than 450,000 deaths (Tao, 2015: www.ncbi.nlm.nih.gov/pubmed/25543329). The most common treatment today is based on monoclonal antibodies, where the dominating therapy HERCEPTIN (trastuzumab) generates annual global sales of US\$ 7 billion. The target product profile of AdaptVac's lead breast cancer project is tailored to be highly competitive both in terms of cost and efficacy, thus aiming at a significant market share.

About AdaptVac ApS

AdaptVac’s technology is a ground-breaking Capsid-Like Particle vaccine platform invented at the University of Copenhagen. The company aims to accelerate the development of highly efficient therapeutic and prophylactic vaccines within high value segments of oncology, infectious diseases and immunological disorders. The company is a joint venture between Expres²ion Biotechnologies and the inventor group NextGen Vaccines, utilizing the synergy between Expres²ion’s recombinant platform and Capsid-based vaccines.

For further information about AdaptVac ApS, please contact:

Dr. Wian de Jongh, CEO
Telephone: +45 26394649
E-mail: wj@adaptvac.com

This press release was submitted for publication through the agency of the contact person set out above on October 17, 2019.